{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:42:05Z","timestamp":1772502125704,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Dalbavancin, albeit indicated for the treatment of skin structure infections, is used for a much wider range of infections. This drug is characterized by a long half-life (more than 200 hours), a favorable safety profile, and an activity against a wide array of gram-positive organisms, including several strains of Staphylococci and Enterococci.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this study, we presented 3 cases of critically ill patients treated with dalbavancin. All patients were therapeutically monitored for plasma dalbavancin concentrations; ultrafiltrate dalbavancin concentrations were assessed in a patient undergoing continuous renal-replacement therapy. Dalbavancin concentrations were measured using a validated liquid chromatographic method coupled with mass spectrometry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>All 3 severely ill patients experiencing necrotizing fasciitis were successfully treated during the acute phase with dalbavancin. Dalbavancin clearance in patient 3 (0.334 L\/h) was considerably increased compared with values measured in the other 2 patients (0.054 and 0.075 L\/h) and with data reported in the literature (0.04\u20130.06 L\/h).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our case reports presented preliminary evidence that dalbavancin can be considered a therapeutic option for necrotizing fasciitis in intensive care unit patients. The role of hypoalbuminemia during dalbavancin exposure merits further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000729","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T10:24:00Z","timestamp":1584699840000},"page":"165-168","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round"],"prefix":"10.1097","volume":"42","author":[{"given":"Alberto","family":"Corona","sequence":"first","affiliation":[{"name":"Intensive Care Unit, ASST Fatebenefratelli Sacco University Hospital Milan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Agarossi","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, ASST Fatebenefratelli Sacco University Hospital Milan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Veronese","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, ASST Fatebenefratelli Sacco University Hospital Milan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, Department of Laboratory Medicine, ASST Fatebenefratelli Sacco University Hospital, Milan and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin\u2014ASL \u201cCitt\u00e0 di Torino\u201d Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17425255.2018.1420162","article-title":"Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections","volume":"14","author":"Galluzzo","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.mcna.2016.03.012","article-title":"New approaches to antibiotic use and review of recently approved antimicrobial agents","volume":"100","author":"Hahn","year":"2016","journal-title":"Med Clin North Am."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ajem.2017.11.037","article-title":"Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit","volume":"36","author":"Koziatek","year":"2018","journal-title":"Am J Emerg Med."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/00498254.2017.1294278","article-title":"Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models","volume":"48","author":"Bhamidipati","year":"2018","journal-title":"Xenobiotica."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.jchromb.2011.07.027","article-title":"Dalbavancin: quantification in human plasma and urine by a new improved high performance liquid chromatography-tandem mass spectrometry method","volume":"879","author":"Alebic-Kolbah","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40261-015-0340-4","article-title":"Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects","volume":"35","author":"Scoble","year":"2015","journal-title":"Clin Drug Investig."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2019","journal-title":"Clin Pharmacol Drug Dev."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:37:35Z","timestamp":1692052655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000729","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}